Cargando…

Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review

BACKGROUND: Nusinersen has been used to treat spinal muscular atrophy type 1 (SMA1) in the UK since 2017. While initial trials showed neuromuscular benefit from treating SMA1, there is little information on the respiratory effects of nusinersen. We aimed to look at the respiratory care, hospital uti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Imran, Gilchrist, Francis J, Carroll, William D, Alexander, John, Clayton, Sadie, Kulshrestha, Richa, Willis, Tracey, Samuels, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Neurodisability
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937078/ https://www.ncbi.nlm.nih.gov/pubmed/31909224 http://dx.doi.org/10.1136/bmjpo-2019-000572

Ejemplares similares

Early neurodevelopmental outcomes of congenital gastrointestinal surgical conditions: a single-centre retrospective study
por: Batta, Vamsi, et al.
Publicado: (2020)

Extreme neonatal hyperbilirubinaemia in refugee and migrant populations: retrospective cohort
por: Wouda, Eva Maria Nadine, et al.
Publicado: (2020)

Neuromuscular electrical stimulation for treatment of dysphagia in infants and young children with neurological impairment: a prospective pilot study
por: Marcus, Sherna, et al.
Publicado: (2019)

Consensus guidelines on managing Rett syndrome across the lifespan
por: Fu, Cary, et al.
Publicado: (2020)

Preterm children’s developmental coordination disorder, cognition and quality of life: a prospective cohort study
por: Uusitalo, Karoliina, et al.
Publicado: (2020)

What families in the UK use to manage attention-deficit/hyperactivity disorder (ADHD): a survey of resource use
por: Fibert, Philippa, et al.
Publicado: (2020)

Developing the FEEDS toolkit of parent-delivered interventions for eating, drinking and swallowing difficulties in young children with neurodisability: findings from a Delphi survey and stakeholder consultation workshops
por: Taylor, Helen, et al.
Publicado: (2022)

Pubertal stage, sex and behaviour in neurodevelopmental disorders versus typical development: a cross-sectional study
por: Penner, Melanie, et al.
Publicado: (2022)

Developing undergraduate autism education for medical students: a qualitative study
por: Dhuga, Yasmin, et al.
Publicado: (2022)

NFL is a marker of treatment response in children with SMA treated with nusinersen
por: Olsson, Bob, et al.
Publicado: (2019)

Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021)

Some Reflections about Electrical Status Epilepticus During Slow-Wave Sleep
por: Posar, Annio, et al.
Publicado: (2022)

Pelizaeus-Merzbacher Disease in a 4-Year-Old Female Child: “A Rare Case Report”
por: Gagan, Devesh, et al.
Publicado: (2023)

Effect of Media Exposure on Social Development in Children
por: Kim, Sung Koo, et al.
Publicado: (2023)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen
por: Lee, Jiwon, et al.
Publicado: (2021)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
por: Pane, Marika, et al.
Publicado: (2021)

Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months
por: De Wel, Bram, et al.
Publicado: (2022)

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
por: Wurster, Claudia D., et al.
Publicado: (2019)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
por: Coratti, Giorgia, et al.
Publicado: (2021)

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients
por: Bonanno, Silvia, et al.
Publicado: (2020)

Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study
por: Gallone, Annamaria, et al.
Publicado: (2022)

Correction: Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen
por: Garofalo, M., et al.
Publicado: (2023)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-up
por: Barp, Andrea, et al.
Publicado: (2020)

Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained?
por: Agosto, Caterina, et al.
Publicado: (2021)

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
por: Scheijmans, Féline E. V., et al.
Publicado: (2022)

A Story of Hope: How a Community Project is Transforming the Lives of Filipino Children With Intellectual and Developmental Disabilities
por: Sese, Lance Vincent C., et al.
Publicado: (2023)

Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
por: Pechmann, Astrid, et al.
Publicado: (2018)

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
por: Kordala, Anna J, et al.
Publicado: (2023)

Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen
por: Brakemeier, Svenja, et al.
Publicado: (2021)

Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen
por: Johannsen, Jessika, et al.
Publicado: (2021)

Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study
por: Walter, Maggie C., et al.
Publicado: (2019)

Successful weaning from the invasive respiratory support after nusinersen treatment in a child with SMA type 1: A case report
por: Pan, Meiling, et al.
Publicado: (2023)

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study
por: Audic, Frédérique, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vuem3iivbj3gelcq1dm7asiji0